Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 27;11(1):47.
doi: 10.1186/s13045-018-0592-6.

Gut microbiome modulates efficacy of immune checkpoint inhibitors

Ming Yi  1 , Shengnan Yu  1 , Shuang Qin  1 , Qian Liu  1 , Hanxiao Xu  1 , Weiheng Zhao  1 , Qian Chu  2 , Kongming Wu  3
Affiliations
Review

Gut microbiome modulates efficacy of immune checkpoint inhibitors

Ming Yi et al. J Hematol Oncol. .

Abstract

Immune checkpoint inhibitors (ICIs) therapy is a novel strategy for cancer treatments in recent years. However, it was observed that most patients treated with ICIs could not get benefit from the therapy, which led to the limitation of clinical application. Motivated by potent and durable efficacy of ICIs, oncologists endeavor to explore the mechanisms of resistance to ICIs and increase the drug sensitivity. It is known that heterogeneity of gut microbiome in populations may result in different outcomes of therapy. In xenograft model, bacteria in gut have been proved as a crucial factor regulating immunotherapy efficacy. And the similar phenomenon was obtained in patients. In this review, we summarized relevant advancements about gut microbiome and ICIs. Furthermore, we focused on modulatory function of gut microbiome in ICIs therapy and possible antitumor mechanism of specific commensals in ICIs treatment. We propose that gut microbiome is an important predictive factor, and manipulation of gut microbiome is feasible to elevate response rate in ICIs therapy.

Keywords: CTLA-4; Gut microbiome; ICIs resistance; Immunotherapy; PD-1/PD-L1.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
The potential mechanism of gut microbiome regulating ICIs efficacy. Firstly, the abundance of CTLA-4 on Tregs is upregulated by some bacteria and metabolites at baseline, which increases sensitivity to CTLA-4 blockade. Secondly, gut microbiota enhances the function of DCs. For example, Bifidobacterium promotes DCs maturation and decreases activation threshold, elevates recruitment and function of T cells by interaction with DCs. Thirdly, administration of Akkermansia muciniphila and Enterococcus hirae results in elevated CD4+ TCM in tumor bed. Fourthly, commensal bacteria are sensed by APCs, inducing pTh17 and Th1 differentiation, which influence tumor immunity by lymphocyte homing and recirculation. Fifthly, SCFAs are utilized by immune cells and gut epithelial cells as source of energy. Lastly, molecule mimicry theory and adjuvant effect participate in immune response
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Brestoff JR, Artis D. Commensal bacteria at the interface of host metabolism and the immune system. Nat Immunol. 2013;14:676–684. - PMC - PubMed
    1. Filyk HA, Osborne LC. The multibiome: the intestinal ecosystem’s influence on immune homeostasis, health, and disease. EBioMedicine. 2016;13:46–54. - PMC - PubMed
    1. Blumberg R, Powrie F. Microbiota, disease, and back to health: a metastable journey. Sci Transl Med. 2012;4:137rv7. - PMC - PubMed
    1. Scher JU, Abramson SB. The microbiome and rheumatoid arthritis. Nat Rev Rheumatol. 2011;7:569–578. - PMC - PubMed
    1. Tai N, Wong FS, Wen L. The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity. Rev Endocr Metab Disord. 2015;16:55–65. - PMC - PubMed

Publication types

MeSH terms

Substances